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Introduction
The treatment of patients with cancer has largely involved
the administration of cytotoxic drugs with narrow therapeutic
indices, with little selectivity for cancer cells over normal
proliferating cells. The primary exception to this has been the
successful administration of hormonal manipulation to treat
breast and prostate malignancies. The development of hormonal
manipulation arose from the observation by Sir George Beatson
that breast carcinomas improved after bilateral oophorectomy.
This led to the use of Tamoxifen and more recently aromatase
inhibitors and oestrogen receptor antagonists. These targeted
therapeutics are characterised by their ability to induce selective
tumour cell death and achieve patient benefit with low toxicity,
and have had a significant impact on the outcome of patients
with early and advanced oestrogen receptor positive breast
cancer.
Further advances in the understanding of tumour cell
biology, the sequencing of the human genome, and the
characterisation of the molecular differences between malignant
and normal cells have, over the past two decades, resulted in
the identification of a large number of critically important
molecular targets. As with the identification of the importance
of oestrogens and the oestrogen receptor, this has accelerated
the development of molecularly targeted therapeutics and is
rapidly revolutionising cancer medicine (Table 1). This brief
review will describe some of the most important advances
achieved and will attempt to predict what future cancer
therapeutics will entail.
Important Targets
Cancer, which comprises several hundred different diseases
that differ in their genetic origin, manifests itself as a
proliferating group of cells that are outside the normal
regulatory framework of growth control. The cancer cell usually
arises by the alteration or mutation of key cellular house-keeping
genes, usually in a series of step-wise genetic changes, resulting
in the increased activity of genes that promote cellular
proliferation and inhibit cell death (called oncogenes) and the
decreased or loss of activity of genes that negatively regulate
cell proliferation (called tumour suppressor genes). This
process, known as carcinogenesis, has been well characterised
for several tumours. The identification of these genetic changes
has allowed the development of anticancer drugs that can target
the function of the cellular proteins involved in driving tumour
growth. The list of relevant targets, which comprises hundreds
of proteins, is rapidly increasing. These include proteins
involved at different points of cell signaling, programmed cell
death (apoptosis), and proteins involved in angiogenesis (the
process by which tumours induce the growth of blood vessels
to provide their blood supply). Drugs specifically targeting these
proteins are now available. These are generally small molecule
inhibitors or antibodies, although antisense and vaccine
technologies are also being evaluated.
The Small Molecule Imatinib (Glivec™):
An Oral Drug Curing Chronic Myeloid
Leukaemia?
Imatinib, marketed by Novartis under the trade name
Glivec™, exemplifies a rationally designed, molecularly targeted
small molecule inhibitor (Figure 1). In 1960, Nowell and
Hungerford described a causal relationship between chronic
myeloid leukaemia (CML) and a consistent chromosomal
abnormality.1  This was identified as a translocation between
chromosomes 22 and 9 that results in abnormally high levels of
activated intracellular signaling by the tyrosine kinase c-Abl.2
Preclinical studies have established this Bcr-Abl translocation
to be the main genetic abnormality driving cellular proliferation
in most CML cells.
Tyrosine kinases such as c-Abl are enzymes that catalyse
the transfer of phosphate from adenosine triphosphate (ATP)
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to tyrosine residues on specific signaling proteins. These
tyrosine amino acid residues function as cellular switches, with
phosphorylation usually resulting in ‘switching on’ of cell
signaling. Chemical compounds that can inhibit the function of
these signaling kinase switches have been developed. Imatinib
(Glivec™) is a small molecule inhibitor of c-Abl that binds to
the ATP-binding site of this kinase, blocking its signaling
function and inducing the cell death of Bcr-Abl positive CML
cells. Clinical trials have confirmed that imatinib induces
complete haematological and cytogenetic responses in patients
with CML. Randomised clinical trials have reported that
imatinib is superior to interferon and cytarabine. Complete
haematological responses were observed in 97% of imatinib
patients compared to 56% in the cytarabine and interferon arm,
with complete cytogenetic responses being reported in 74% of
the Imatinib arm compared to 8% in the interferon and
cytarabine arm.3  Responses to imatinib were rapid with most
patients achieving a complete haematologic response within the
first 4 to 6 weeks of therapy.   Imatinib is administered orally,
twice daily and is well tolerated with minimal toxicity.3   It is
now the standard of care for the first line treatment of patients
with CML. It is hoped that many of the patients achieving
cytogenetic complete responses from imatinib therapy will be
cured of the disease. Imatinib is also active in patients with
transformed CML. However, it is less active in this setting,
presumably because the tumour cells have by this stage
developed other genetic changes and the reversal of Abl
signaling alone is no longer able to block tumour cell
proliferation.
Imatinib is also active in the treatment of gastrointestinal
stromal tumours (GIST) - a tumour type that is being diagnosed
with increasing frequency. This neoplasm can arise from any
organ in the gut, or from the omentum or mesentery and is
highly refractory to chemotherapy and radiotherapy. It is rapidly
fatal unless curative surgery is feasible. Abnormal activation of
the transmembrane receptor c-KIT by constitutive mutations
occurs in the majority of GISTs, leading to uncontrolled tumour
growth. c-KIT is another tyrosine kinase enzyme switch that
can also be inhibited by the chemical imatinib. A study of 147
patients with unresectable GIST treated with imatinib reported
a partial response rate in 66% of patients and an additional 17%
of patients had minor responses or stable disease.4    KIT and
PDGFRα mutational status were highly significant in predicting
response.  The patients have been followed up for a median of
21 months so the durability of response is not yet known.
However, while secondary resistance and late progression is
seen in GIST patients treated with imatinib, most remain on
the drug for a prolonged period.
Many other small molecule chemical inhibitors of various
key cellular proteins involved in tumour growth are now being
evaluated in the clinic. Gefitinib (Iressa™, AstraZeneca) blocks
epidermal growth factor signaling (erbB1 or EGFR) and has been
approved for the treatment of patients with non-small cell lung
carcinoma. There are high expectations that these novel agents
will have a major impact on the care of cancer patients.
Table 1: Examples of Recognised Important Targets ‘Hijacked’ by Tumour Cells
Target Molecular alteration Tumour type Therapeutic
HER2 DNA Amplification Breast Trastuzumab (Herceptin)
Bcr-Abl Chromosomal Translocation Chronic Myeloid Leukaemia Imatinib (Glivec)
Bcl-2 Chromosomal Translocation Follicular non-Hodgkin’s Lymphoma Bcl-2 antisense (Genasense)
c-Kit Activating kinase mutation GI stromal tumours (GIST) Imatinib (Glivec)
B-Raf Activating kinase mutation Melanoma BAY 43-9006
VEGFR Loss of VHL Tumour suppressor Renal BAY 43-9006; Bevacuzimab (Avastin)
Ras Activating mutation Colorectal, pancreas
EGFR Activating mutation Glioblastoma multiforme Erlotinib (Tarceva)
Figure 1: Two-dimensional chemical structure
of Imatinib (Glivec™)
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Figure 2:  Schematic representation of humanised mouse monoclonal antibodies. In the case of the chimeric antibody, the
intact rodent variable regions (grey) are attached to human constant (FC) regions (black). In fully humanised antibodies, the
antigen binding regions from the rodent antibody variable region, called complimentarity determining regions (CDR) (3 in
the heavy chain and 3 in the light chain [grey]), are combined with a human antibody that does not contain any mouse
protein sequences and should, therefore, not be immunogenic
Mouse monoclonal antibody Chimeric
(partially humanised)
monoclonal antibody
Fully humanised  antibody
The Antibodies Trastuzumab (Herceptin™)
and Cetuximab (Erbitux™)
An alternative means of targeting key cellular proteins is
through the development of monoclonal antibodies against the
protein of interest. These antibodies were initially generated by
immunising mice to raise monoclonal antibodies to the target
human receptor. To overcome the development of a human anti-
mouse antibody (HAMA) immune response against murine
monoclonal antibodies in treated patients, human or mouse
chimeric (or partially ‘humanised’) antibodies have been
produced. These primarily retain the small portion of the murine
protein sequences responsible for antigen binding, with the
remainder of the molecule being composed of human
immunoglobulin (Figure 2). Fully humanised monoclonal
antibodies have also been produced, for example ABX-EGF
(Abgenix, Inc), using the Xenomouse™ transgenic strain. These
antibodies do not contain mouse protein sequences and should
not be immunogenic. Therefore they have a slower clearance
rate than mouse or mouse-derived monoclonal antibodies,
facilitating repeat administration.
In 1962, Stanley Cohen isolated a novel protein, now known
as epidermal growth factor (EGF), from the submaxillary gland
of mice. It promoted accelerated eruption of incisors and eyelid
opening in newborn animals.5   After four decades of research,
it is now known that EGF and its family of related receptors
(EGFR, HER2, erbB3 and erbB4) play an important role in the
modulation of tumour cell proliferation and apoptosis. They are
normally found on epithelial cells but are often over-expressed
in tumour cells. Drugs that target these receptors, and their
downstream signalling pathways, are widely viewed as potential
anticancer therapeutic agents.
One third of breast cancers overexpress human epidermal
growth factor receptor 2 (HER2) due to HER2 gene
amplification (high copy number of HER2 DNA).6  This is
associated with an inferior prognosis, with shorter disease-free
and overall survival. A recombinant monoclonal antibody,
trastuzumab, targets this receptor. Patients randomised to
receive chemotherapy with trastuzumab as first line therapy in
metastatic disease, when compared to patients receiving
chemotherapy alone, have improved response rates and
survival.7  Also, when used as a single agent, trastuzumab
produces durable objective responses in women who had not
previously received chemotherapy for their metastatic disease.6
However, only breast cancer patients with HER-2 gene
amplification significantly benefit from trastuzumab.
Trastuzumab is largely non-toxic although it has been
uncommonly associated, in patients previously exposed to the
anthracycline doxorubicin (adriamycin), with cardiac toxicity
usually manifested as asymptomatic decreases in the left
ventricular ejection fraction.8   These decreases appear to be
reversible and are probably related to the role of HER2 signaling
in cardiac repair and remodelling following anthracycline
induced injury. The clinical role of trastuzumab in other tumour
types overexpressing HER2 is being explored, and may
important in a small subgroup of patients with non-small cell
lung carcinoma.
Cetuximab is a monoclonal antibody directed against the
extracellular domain of the EGF receptor (EGFR). It arrests cells
in the G1 phase of the cell cycle, inhibiting the growth of EGFR
expressing tumour cells.9   A recent trial randomised 329 heavily
pre-treated patients, with histologically proven metastatic
colorectal carcinoma, that progressed whilst on or within 3
months of an irinotecan-based regimen, to receive either
cetuximab alone or cetuximab with irinotecan. All the patients
had EGFR expressing tumours. The researchers found that
22.9% of patients who received combination treatment of
cetuximab and irinotecan had a partial response and tumour
growth was delayed by approximately 4.1 months. For patients
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who received cetuximab alone, the tumour response rate was
10.8% and tumour growth was delayed by 1.5 months.10
Cetuximab is well tolerated: allergic reactions and a reversible
acne-like skin rash are the most relevant side effects.10
In February 2004, the US Food and Drug Administration (FDA)
approved cetuximab for use in patients with colorectal
carcinoma. The FDA has also approved a diagnostics kit for the
assessment of the EGFR status of patients’ tumours.
Anti-angiogenesis and
the Antibody Bevacizumab (Avastin™)
Anti-angiogenic drugs are another exciting development in
the armamentaria to treat cancer. Bevacizumab is a recombinant
humanised monoclonal antibody against vascular endothelial
growth factor (VEGF), a protein that promotes growth of blood
vessels, which tumours need to survive. In a study of 815 patients
with colorectal cancer treated with a standard chemotherapy
regimen of irinotecan, fluorouracil and folinic acid (IFL), the
addition of bevacizumab was shown to confer a survival
advantage.11   Patients treated with the bevacizumab
combination had a median overall survival of 20.3 months, while
patients treated with standard chemotherapy alone had a
median survival of 15.6 months. Tumours were reduced in size
by at least half in 45% of patients who received bevacizumab
and in 35% of patients who received chemotherapy alone.
Overall, more patients receiving the bevacizumab combination
responded to treatment (44.9% versus 34.7%) and their
response was maintained for longer (10.4 months versus 7.1
months). All differences were statistically significant. The
incidence of gastrointestinal perforation, though rare, may be
increased by the addition of bevacizumab to IFL. High blood
pressure was higher in patients treated with the bevicizumab
combination (22.4% and 8.3%; p < 0.01), but was easily
managed with oral anti-hypertensive medication.
 Conclusion
Over two hundred new anticancer molecular targeted drugs
are at present being evaluated in clinical trials. An even larger
number of compounds are undergoing preclinical tests. Their
greatest value will probably lie in their use in strategically
selected combinations based on tumour biology. Improved
diagnostics and therapeutics are rapidly changing the treatment
of patients with cancer, and it is envisioned that cancer survival
will increase in the years ahead.
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